RESEARKA

Several unresolved questions complicate the translational trajectory of Curcumin inflammaging from bench to bedside. First, the mechanism-to-function translation gap remains wide: preclinical models consistently demonstrate NF-κB inhibition and downstream anti-inflammatory effects, yet human trials frequently report null or inconsistent findings on the same biomarkers, raising the question of whether Curcumin inflammaging achieves sufficient target engagement in vivo or whether the mechanistic story is incomplete. Second, dose-response relationships are poorly characterized; the present corpus includes trials administering doses ranging from 80 mg/day of nano-curcumin (Gerami 2025) to 1500 mg of hydrolyzed curcumin (Helder 2025), with no systematic evidence identifying an optimal therapeutic window. Third, the duration of most trials—typically 8 to 16 weeks—is short relative to the chronicity of inflammaging as a biological process, raising the possibility that longer interventions might be required to observe clinically meaningful effects on healthspan-relevant endpoints. Tradeoffs also merit consideration: curcumin's safety profile is generally favorable, but the absence of long-term safety data in older adult populations, combined with the potential for drug-supplement interactions in polypharmacy regimens, warrants cautious interpretation. The tension between curcumin's accessibility and the rigor of evidence supporting its use in aging populations appears to be a defining feature of the field as currently constituted.

Citation Support

• source_1 Flensted-Jensen 2025
• source_2 Flensted-Jensen 2025b
• source_3 Xu 2025
• source_4 El-Rakabawy 2025
• source_5 Schonenberger 2025